Navco Pharmaceuticals Inc.
NAV.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 641.40K | 1.11M | 1.41M | 1.17M | 1.04M |
| Depreciation & Amortization | 54.10K | 61.80K | 44.20K | 32.30K | 32.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 695.40K | 1.17M | 1.46M | 1.20M | 1.07M |
| Operating Income | -695.40K | -1.17M | -1.46M | -1.20M | -1.07M |
| Income Before Tax | -1.27M | 371.80K | -1.99M | -1.73M | -1.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.27 | 0.37 | -1.99 | -1.73 | -1.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.27M | 371.80K | -1.99M | -1.73M | -1.60M |
| EBIT | -695.40K | -1.17M | -1.46M | -1.20M | -1.07M |
| EBITDA | -638.30K | -1.12M | -1.42M | -1.17M | -1.04M |
| EPS Basic | -0.02 | 0.01 | -0.05 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | 0.01 | -0.05 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 206.60M | 189.84M | 174.78M | 135.55M | 116.54M |
| Average Diluted Shares Outstanding | 206.60M | 189.84M | 174.78M | 135.55M | 116.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
